Big things sometimes come in small packages. For Sirtex Medical, the big thing comes in a really small package.
The Australian medical device company’s flagship product - the SIR-sphere - is made up of 30 to 60 million microspheres about the size of a grain of sand, which are injected into the hepatic artery and flow into the liver where they kill tumors from the inside.
In this episode of DeviceTalks, MassDevice.com publisher Brian Johnson talks with Mangano about the company, the learning curve he had of moving from a traditional medical device company to an oncology company and why the cancer market may be ripe for other medtech companies to enter.
Top comments
The DeviceTalks Podcast Network is the ultimate destination for all things #MedTech. By subscribing to this single feed, you’ll gain access to every podcast in our diverse and growing portfolio—more than a dozen unique shows featuring senior leaders, groundbreaking technology insights, and in-depth discussions on the most important topics in the medical device industry.
Each episode dives deep into critical areas like business strategy, market trends, surgical robotics, orthopedics, structural heart, neurology, and beyond. You’ll hear from leading voices at top companies—ranging from major OEMs to innovative startups—sharing their solutions, stories, and strategies for tackling the indust...